Phase 2 trial of TAK-385, an oral GnRH antagonist, in prostate cancer

At the European Cancer Congress (ECC) 2015, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the first interim analysis of a phase 2, randomised, open-label, parallel group clinical trial of TAK-385, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of patients with advanced prostate cancer.

Year of Production:
Running Time:
Color/Sound:

2015
04:24
Color/Sound

Comments are closed.